Business Standard

Thursday, December 19, 2024 | 06:38 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Bayer brings kidney disease treatment drug to India at 1/15th US cost

Brand named Kerendia (finerenone) will cost Rs 97.5 per day as treatment cost in India

Bayer
Premium

The Bayer AG logo sits on display at the headquarters in La Garenne-Colombes, near Paris, France. Photo: Reuters

Sohini Das Mumbai
German firm Bayer is bringing to India a drug to treat chronic kidney disease associated with diabetes patients and costing one-fifteenth of the price in the US.

Brand named Kerendia (Finerenone) will cost Rs 97.5 per day. “The recent Indian Chronic Kidney Disease (ICKD) study identifies diabetes as the leading cause of chronic kidney disease and end-stage kidney disease in India. Over 40% of all patients with diabetes will develop chronic kidney disease. Seventy-four million people suffer from diabetes in India and this figure is likely to increase to ninety-three million by 2030, making it an epidemic,” Bayer said.

After China, India

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in